MentionFox
Home › Executive changes › Vera Therapeutics, Inc.
Leadership changes · VERA · SEC Form 8-K, Item 5.02

Leadership changes at Vera Therapeutics, Inc. (2026)

Before you join, sell to or invest in Vera Therapeutics, Inc.

MentionFox check on Vera Therapeutics, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/vera-therapeutics

Check Vera Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Vera Therapeutics, Inc.?

Who joined and who left Vera Therapeutics, Inc. (VERA)? 2 appointments reported from 2026-03-09 to 2026-07-09, each cited to the company's own filing.

Christopher Hite was appointed Director of Vera Therapeutics, Inc. As of November 14, 2026, Vera Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 9, 2026 to July 9, 2026, naming 2 appointments (Form 8-K, March 9, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company ↓

Sell to companies like Vera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes3
In (appointed)2
Latest filing2026-07-09

Vera Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-09 to 2026-07-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Vera Therapeutics, Inc. files it.

Also on the record for Vera Therapeutics, Inc.

DateRecordFigureOur pageSource
November 10, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION4.6% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Kynam Capital Management, LP4.01% of the class5%+ stakesSource
August 7, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION5.8% of the class5%+ stakesSource
July 30, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.7.4% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc.6.4% of the class5%+ stakesSource
April 1, 2026Stake report, Schedule 13G, by Point72 Asset Management, L.P.1.7% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
March 11, 2026Stake report, Schedule 13G, by Deep Track Capital, LP5.5% of the class5%+ stakesSource
March 5, 2026Stake report, Schedule 13D/A, by Sofinnova Venture Partners X, L.P. ("SVP X")4% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc.7.7% of the class5%+ stakesSource
February 5, 2026Stake report, Schedule 13G/A, by FMR LLC4.1% of the class5%+ stakesSource
January 30, 2026Stake report, Schedule 13G, by The Vanguard Group5.03% of the class5%+ stakesSource

Selling to them or working with them? See who runs Vera Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Vera Therapeutics, Inc. and the records around it.

Vera Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Vera Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Vera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vera Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-07-09Reportednot named in the filing8-K, 2026-07-09
2026-03-09InDirector8-K, 2026-03-09
2026-03-09In8-K, 2026-03-09

Who leads Vera Therapeutics, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Vera Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Vera Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Vera Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Vera Therapeutics, Inc., with the record behind each one.

Find candidates like Director at Vera Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-07-09 · 8-K

Reported

Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as the Company's Chief Regulatory Officer, effective as of August 3, 2026.

Also stated in this filing

  • On July 9, 2026, Vera Therapeutics, Inc. (the "Company") announced that William Turner will no longer serve as the Company's Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026.
Filed 2026-03-09 · 8-K

Appointed: Christopher Hite, Director

On March 5, 2026, the board of directors (the "Board") of Vera Therapeutics, Inc. (the "Company") appointed Christopher Hite to the Board, effective immediately.

Appointed: Christopher Hite

Mr. Hite will serve as a Class III Director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.

Also stated in this filing

  • Contingent upon and effective as of Mr. Hite's appointment to the Board, Mr. Hite was automatically granted a nonstatutory stock option award (the "Option Grant") to purchase 24,937 shares of the Company's Class A common stock ("Common Stock") with a per-share exercise price of $38.85, pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (as it may be amended from time to time, the "Policy").
  • The Option Grant will vest monthly over a three-year period, subject to Mr. Hite's continuous service as of each such vesting date, and is otherwise subject to the same terms set forth in the Policy for initial grants to new directors.
  • In addition, in accordance with the Policy, Mr. Hite will also receive an annual cash retainer of $45,000 for his service on the Board which will be pro-rated for 2026.
  • Pursuant to the Policy, commencing with the Company's 2027 Annual Meeting of Stockholders, Mr. Hite will be eligible to receive an annual option grant to purchase the lesser of (i) 18,000 shares of Common Stock and (ii) the maximum number of shares of Common Stock that would result in the option having a grant date fair value of not more than $400,000, subject to his continuous service as of such date.

Tools for this story

Each opens in a new tab, filled in for Vera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/vera-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Vera Therapeutics, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/vera-therapeutics